SEPN · Septerna, Inc.

Septerna’s Q1 2026 results reflect a pivotal inflection point: revenue surged to $26.5 million—driven almost entirely by the Novo Nordisk collaboration—including $15.7 million in amortization of the $195.0 million upfront payment and $10.3 million for ongoing research services—marking meaningful progress in converting partnership value into recognized income. The net loss narrowed sharply to $8.6 million from $21.5 million year-over-year, primarily due to this revenue ramp, even as R&D expenses increased 53% to $29.5 million, reflecting active clinical investment across SEP-631 and SEP-479. Management explicitly tied the improved financial profile to pipeline execution, highlighting that positive Phase 1 data for SEP-631—including robust, dose-dependent suppression of skin wheal formation and favorable PK supporting once-daily dosing—validated its Native Complex Platform® and enabled rapid progression toward a Phase 2b CSU trial in H2 2026. Simultaneously, the April 2026 initiation of the SEP-479 Phase 1 trial in healthy volunteers represents the company’s second clinical-stage asset, broadening its endocrinology footprint beyond hypoparathyroidism into potential future indications. The $522.1 million cash position—down modestly from $548.7 million at year-end—provides substantial operational flexibility, with management reaffirming a runway extending at least into 2029, which supports advancing both programs through key clinical readouts without near-term financing risk. The announced transition of CMO Jae Kim introduces a leadership consideration, though his continued advisory role mitigates immediate execution risk; the timing coincides with heightened clinical activity, underscoring the importance of timely succession planning for upcoming regulatory interactions and trial expansions.